Man Boobs and Low Testosterone: Causes and Treatment

Man boobs as a sign of low testosterone is a common concern, but the reality is more nuanced. Enlarged breast tissue in men, known medically as gynaecomastia, is usually caused by an imbalance between oestrogen and testosterone rather than low testosterone alone. While hypogonadism is one recognised cause, obesity, certain medicines, liver disease and other hormonal conditions can all play a role. Understanding the distinction between glandular gynaecomastia and fatty pseudogynaecomastia is essential, as the two conditions have different causes and treatment pathways. This article explains what drives breast tissue changes in men and what to do if you are concerned.

What causes man boobs, and is low testosterone to blame?

Man boobs are most often caused by an oestrogen-to-testosterone imbalance rather than low testosterone alone. Common causes include puberty, obesity, certain medicines and liver disease, and many cases are idiopathic.

Man boobs can be a sign of low testosterone, but they are more commonly caused by an imbalance between oestrogen and testosterone rather than low testosterone alone. The medical term for enlarged breast tissue in men is gynaecomastia, which occurs when glandular breast tissue grows in response to a relative excess of oestrogen compared with testosterone.^[1][2] This is distinct from pseudogynaecomastia, where the appearance of enlarged breasts is due to excess fatty tissue rather than glandular growth.

Testosterone naturally suppresses oestrogen activity in male breast tissue. When testosterone levels fall, or when oestrogen levels rise disproportionately, the balance tips and glandular tissue can develop. Obesity contributes by increasing aromatase activity in fatty tissue, which converts androgens to oestradiol.^[2][3] Low testosterone (also called hypogonadism) is one recognised cause, but it is far from the only one. Other common causes include:

• Puberty, when hormonal fluctuations are normal and usually resolve within two years

• Obesity, which increases the conversion of androgens to oestrogen in fatty tissue

• Certain medicines, including spironolactone, cimetidine, finasteride, dutasteride, anti-androgens, GnRH analogues, some antipsychotics, anabolic steroids, opioids and some antiretrovirals; this list is not exhaustive and a pharmacist or GP can advise on specific medicines^[1][3]

• Excessive alcohol use, which can affect hormone metabolism

• Liver or kidney disease, which can alter hormone metabolism

• Tumours of the testes, adrenal glands or pituitary gland

• Klinefelter syndrome, a genetic condition affecting testosterone production

In many cases, no underlying cause is identified, and the condition is described as idiopathic. It is important not to assume that man boobs automatically indicate low testosterone, as the hormonal picture is often more complex. A GP assessment is the appropriate first step to identify the underlying cause and guide further investigation. Further information is available from the NHS and NICE Clinical Knowledge Summary on gynaecomastia.

How do doctors tell the difference between gynaecomastia and excess fat?

Doctors distinguish gynaecomastia from pseudogynaecomastia by clinical examination: glandular tissue feels firm and disc-like beneath the nipple, whereas fatty tissue is soft and diffuse. Blood tests, testicular examination and imaging may follow.

Doctors distinguish between gynaecomastia and pseudogynaecomastia primarily through clinical examination, as the two conditions have different underlying causes and different treatment pathways. In gynaecomastia, a firm or rubbery disc of glandular tissue can be felt beneath the nipple and areola, often described as a button-like mass. In pseudogynaecomastia, the tissue feels soft and fatty throughout, without a distinct glandular component, and is distributed more diffusely across the chest.

A GP will typically begin with a thorough history and physical examination, asking about:

• Duration and rate of onset of breast enlargement

• Medicines, including recreational drugs and supplements

• Symptoms of underlying conditions, such as fatigue, reduced libido or testicular changes

• Family history of hormonal or genetic conditions

A focused testicular examination is an essential part of the assessment, as testicular tumours are an important cause of gynaecomastia. Testicular ultrasound should be arranged promptly if a mass is suspected on examination.

If gynaecomastia is confirmed or suspected, blood tests are usually arranged to assess hormone levels, including testosterone, sex hormone-binding globulin (SHBG) and albumin (to allow calculation of free testosterone or the free androgen index when total testosterone is borderline or SHBG is abnormal), oestradiol, luteinising hormone (LH), follicle-stimulating hormone (FSH), prolactin, thyroid function and serum human chorionic gonadotrophin (hCG) to screen for hCG-secreting tumours. Liver and kidney function tests may also be requested.

Breast imaging such as mammography or ultrasound may be considered if the clinical picture is unclear or if there are features that raise concern. In line with NICE NG12 guidance on suspected cancer recognition and referral, men with features such as a hard, irregular or rapidly growing mass, nipple discharge or retraction, skin changes, or unilateral breast changes (particularly in men aged 50 or over) should be referred promptly under the two-week-wait pathway, as male breast cancer, though rare, must be excluded.^[7] Most cases of gynaecomastia are benign, but a careful assessment ensures that serious causes are not missed.

What are the other signs of low testosterone in men?

Low testosterone commonly causes reduced libido, erectile dysfunction, fatigue, low mood, reduced muscle mass and increased abdominal fat. These symptoms are non-specific and require blood testing to confirm the diagnosis.

Low testosterone in men produces a range of symptoms beyond breast tissue changes, and recognising the broader picture helps both patients and clinicians identify when investigation is warranted. The most commonly reported symptoms include reduced libido, reduced frequency of morning erections, erectile dysfunction, fatigue, low mood and difficulty concentrating. These symptoms are non-specific and can overlap with many other conditions, which is why blood testing is essential before a diagnosis is made.

Physical signs of low testosterone may include:

• Reduced muscle mass and strength, even with regular exercise

• Increased body fat, particularly around the abdomen

• Decreased body and facial hair

• Reduced testicular size

• Hot flushes or sweating, particularly in men with abrupt testosterone decline

• Reduced bone density, which increases the risk of osteoporosis over time

• Infertility or subfertility

• Unexplained anaemia

Psychological symptoms are also common and can be significant. Men with low testosterone may experience low mood, irritability, poor motivation and reduced sense of wellbeing. Sleep disturbance and reduced energy are frequently reported. In younger men, delayed puberty or incomplete sexual development may be the presenting concern. The presence of several consistent symptoms together, particularly when combined with physical signs, increases the likelihood that hormonal investigation will be informative.

It is worth noting that many of these symptoms are also associated with obesity, depression, sleep apnoea, type 2 diabetes and other common conditions. Men who are concerned about any of these symptoms should speak to their GP rather than self-diagnosing, as the causes are varied and treatment depends on accurate identification of the underlying problem. The NHS and NICE Clinical Knowledge Summary on testosterone deficiency provide further guidance on symptom profiles and when to investigate.

How is low testosterone diagnosed and treated on the NHS?

Diagnosis requires at least two low morning testosterone readings alongside symptoms; treatment may include TRT, addressing reversible causes or endocrinology referral. TRT is not suitable for men with prostate or breast cancer, and fertility implications must be discussed.

Low testosterone is diagnosed on the NHS through blood testing. The British Society for Sexual Medicine (BSSM) and NICE guidance recommend that total testosterone is measured in a morning fasting sample, as levels follow a diurnal pattern and are highest in the early morning.^[8] A single low result is not sufficient for diagnosis; at least two separate morning samples showing consistently low testosterone, alongside symptoms, are required before treatment is considered.^[8][9] Where SHBG is abnormal or total testosterone is borderline, free testosterone or the free androgen index should be calculated using SHBG and albumin measurements. Reference ranges vary between laboratories, but a total testosterone below approximately 8 to 12 nmol/L is generally considered low depending on clinical context, in line with BSSM guidance.

Once hypogonadism is confirmed, the NHS treatment pathway depends on whether the cause is primary (originating in the testes) or secondary (originating in the pituitary or hypothalamus). Treatment options include:

• Testosterone replacement therapy (TRT), available in the UK as gels and injections; patches and implants exist but their availability and commissioning vary, and a prescriber can advise on what is accessible locally

• Addressing reversible causes, such as stopping causative medicines, treating obesity or managing an underlying condition

• Referral to endocrinology, for complex cases or where fertility preservation is a concern

Important cautions apply before starting TRT. It should not be used in men with known or suspected prostate cancer or breast cancer.^[9] TRT suppresses sperm production, so men who wish to preserve fertility should discuss this with their clinician before starting treatment; referral to a specialist and consideration of sperm banking may be appropriate.^[10][11]

NHS access to TRT is guided by clinical need, and not all men with borderline testosterone levels will be offered replacement therapy. Monitoring during treatment typically includes testosterone levels, haemoglobin and haematocrit (as TRT can increase red blood cell production), and prostate-specific antigen (PSA), with checks at baseline, at around three to six months after starting treatment, and then annually once stable, in line with UK guidance. Symptom review is an ongoing part of monitoring.

Patients taking TRT who experience unexpected or concerning side effects are encouraged to report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Men who suspect low testosterone should begin by speaking to their GP, who can arrange appropriate blood tests and refer to secondary care if needed.

Can man boobs be reduced, and what treatments are available in the UK?

Man boobs can often be reduced by treating the underlying cause, with lifestyle changes, off-label SERMs under specialist supervision, or surgery for persistent cases. NHS funding for gynaecomastia surgery depends on local ICB criteria.

Man boobs can be reduced in many cases, and the most appropriate treatment depends on whether the underlying cause is gynaecomastia, pseudogynaecomastia or a combination of both. Addressing the root cause is always the first priority. If a medicine is responsible, switching to an alternative under medical supervision may lead to gradual resolution. If low testosterone is confirmed, testosterone replacement therapy may help restore the hormonal balance, though established glandular tissue does not always regress fully once it has formed.

For pseudogynaecomastia caused by excess body fat, lifestyle changes including a calorie-controlled diet and regular physical activity remain the cornerstone of management. Weight loss reduces the fatty tissue contributing to the appearance and also lowers oestrogen production from adipose tissue, which may benefit true gynaecomastia as well.

Where gynaecomastia persists despite addressing underlying causes, medical treatments have been used off-label in some cases. Selective oestrogen receptor modulators (SERMs) such as tamoxifen and raloxifene have been studied and may reduce glandular tissue, particularly in early or actively growing gynaecomastia, though they are not licensed for this indication in the UK.^[12] Their use should only be considered under specialist supervision, with appropriate counselling on risks and monitoring. Men should not attempt to obtain SERMs, anabolic steroids or other hormonal preparations from unregulated online sources, as this carries significant safety risks; any treatment should be arranged through a regulated UK healthcare provider.

Surgical options are available for men with persistent, symptomatic or longstanding gynaecomastia. These include:

• Liposuction, for predominantly fatty tissue

• Glandular excision, for true gynaecomastia with a firm glandular component

• A combination of both, in many cases

NHS funding for gynaecomastia surgery is not routinely available and depends on local Integrated Care Board (ICB) policies and NHS Evidence-Based Interventions (EBI) criteria. Patients should check with their GP or local ICB what criteria apply in their area. Private surgical options are available across the UK.

Men seeking guidance on weight management as part of a broader approach to this condition may find it helpful to consult a clinician. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed. Any concerns about breast changes should be assessed by a GP in the first instance, and men noticing a hard, rapidly growing or one-sided lump, nipple discharge or skin changes should contact their GP promptly rather than waiting.

Scientific References

1. Gynaecomastia.
2. Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment.
3. Gynecomastia: physiopathology, evaluation and treatment.
4. Gynecomastia in Infants, Children, and Adolescents.
5. Klinefelter syndrome.
6. Tremor Associated With Klinefelter Syndrome: Report of a Case Treated by Deep Brain Stimulation and Systematic Review of the Literature.
7. Suspected cancer: recognition and referral (NG12).
8. Analysis of diurnal variation in serum testosterone levels in men with symptoms of testosterone deficiency.
9. Testosterone Enantate 250 mg/ml Solution for Injection.
10. Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review.
11. Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis.
12. Tamoxifen | Drugs – BNF – NICE.
13. The 'male menopause'.

Frequently Asked Questions